Table 2.
Landscape of candidate mucosal vaccines in clinical development based on WHO data [2].
| Name of the Vaccine |
Form | Developers | Route of Administration |
Clinical Trials Phase |
|---|---|---|---|---|
| Covishield | Viral vector (non-replicating) | University of Oxford | IN | I |
| VXA-CoV2-1 Ad5 | Viral vector (non-replicating) | Vaxart | ORAL | II |
| DelNS1-2019-nCoV-RBD-OPT 1 | Viral vector (replicating) | University of Hong Kong; Xiamen University; Beijing Wantai Biological Pharmacy |
IN | III |
| bacTRL-Spike | DNA based | Symvivo Corporation | ORAL | I |
| COVI-VAC | Live attenuated virus | Codagenix; Serum Institute of India |
IN | III |
| CIGB-669 | Protein subunit | Center for Genetic Engineering and Biotechnology | IN | I/II |
| Razi Cov Pars | Protein subunit | Razi Vaccine and Serum Research Institute | IM and IN | III |
| BBV154 | Viral vector (non-replicating) | Bharat Biotech International Limited | IN | I |
| MV-014-2012 | Live attenuated virus | Meissa Vaccines, Inc. | IN | I |
| - | Inactivated virus | Laboratorio Avi-Mex | IM or IN | I |
| CoV2-OGEN1 | Protein subunit | USSF; Vaxform |
ORAL | I |
| - | Viral vector (non-replicating) | CyanVac LLC | IN | I |
| - | Bacterial antigen-spore expression vector | DreamTec Research Limited | ORAL | NA |